- Home
- PBYI vs SANG Comparison
PBYI vs SANG Comparison
Compare PBYI & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SANG
- Stock Information
- Founded
- PBYI 2010
- SANG 1984
- Country
- PBYI United States
- SANG Canada
- Employees
- PBYI N/A
- SANG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SANG Computer Software: Programming Data Processing
- Sector
- PBYI Health Care
- SANG Technology
- Exchange
- PBYI Nasdaq
- SANG Nasdaq
- Market Cap
- PBYI 176.1M
- SANG 170.7M
- IPO Year
- PBYI N/A
- SANG 2021
- Fundamental
- Price
- PBYI $2.50
- SANG $6.34
- Analyst Decision
- PBYI Strong Buy
- SANG Buy
- Analyst Count
- PBYI 1
- SANG 2
- Target Price
- PBYI $7.00
- SANG $5.63
- AVG Volume (30 Days)
- PBYI 330.8K
- SANG 8.0K
- Earning Date
- PBYI 10-31-2024
- SANG 09-18-2024
- Dividend Yield
- PBYI N/A
- SANG N/A
- EPS Growth
- PBYI N/A
- SANG N/A
- EPS
- PBYI 0.18
- SANG N/A
- Revenue
- PBYI $219,143,000.00
- SANG $250,030,000.00
- Revenue This Year
- PBYI N/A
- SANG N/A
- Revenue Next Year
- PBYI N/A
- SANG $3.05
- P/E Ratio
- PBYI $13.95
- SANG N/A
- Revenue Growth
- PBYI N/A
- SANG N/A
- 52 Week Low
- PBYI $2.13
- SANG $2.18
- 52 Week High
- PBYI $7.73
- SANG $6.40
- Technical
- Relative Strength Index (RSI)
- PBYI 42.87
- SANG 70.22
- Support Level
- PBYI $2.45
- SANG $5.15
- Resistance Level
- PBYI $2.63
- SANG $5.50
- Average True Range (ATR)
- PBYI 0.14
- SANG 0.25
- MACD
- PBYI 0.06
- SANG 0.09
- Stochastic Oscillator
- PBYI 65.85
- SANG 97.18
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable Internet protocol communications systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes Cloud Services, Video Conferencing, Carrier Services, Business Phone Systems, Phones & Devices, and Network Connectivity. The company sells into three major geographic centers: the United States of America, which is the key revenue driver, Canada, and other foreign countries.